Targeted therapy for Vitiligo

Research conducted at Ahammune has led us to identify cellular pathways deregulated in vitiligo. Our strategy is to restore these pathways to their homeostatic state using small molecules to maintain skin health.

Ahammune’s lead drug candidate, AB1001 is an Investigational New Drug being developed as a topical therapy for vitiligo. It has “first-in class” mechanism of action that targets pathways involved in triggering autoimmunity in vitiligo. Phase I clinical studies will be initiated with AB1001 in 2021.

 

Vitiligo is the most common depigmenting disorder with a global prevalence of about 1-2 percent of the population. It is a lifelong disease with no cure.

 

The chronic nature of the disease involves unpredictable recurrent episodes of trigger where immune cell mediated death of pigment-producing cells called melanocytes occur in skin. This leads to the development and spread of white patches. The current treatments for vitiligo available in market provide only temporary and symptomatic relief, leading to an enormous unmet global need for treatment.

 

Ahammune’s aim is to arrest the progress of Vitiligo and to induce re-pigmentation of depigmented patches through its targeted therapy. The company is developing new chemical entities as targeted therapy for vitiligo.

Ahammune’s molecules is aimed to arrest new immune triggers that destroy melanocytes by effector T cells. Thus, by targeting the activation step of immune cells, our molecules would prevent further killing and spread of depigmentation.

The research conducted at Ahammune has led us to identify cellular pathways deregulated in vitiligo. Our strategy is to restore these pathways to their homeostatic state using small molecules to maintain skin health.

Our molecules tackle the problem of new immune triggers where melanocyte killing is done by effector T cells. By targeting the activation step of immune cells, our molecules prevent further killing and spread of depigmentation.